Please login to the form below

Not currently logged in
Email:
Password:

S-A/ Avila sign oncology drug deal

Sanofi-aventis has announced a worldwide strategic alliance with Avila Therapeutics focusing on the discovery of covalent drugs for cancers

Sanofi-aventis (S-A) has announced a worldwide strategic alliance with Avila Therapeutics focusing on the discovery of covalent drugs for use in oncology treatments.

The deal allows S-A to obtain a global licence to develop and market compounds resulting from the partnership. Avila will receive up to $40m in upfront and support payments, with milestone payments of up to $154m per collaboration programme also available if the developed product is approved in the US, Europe and Japan.

There will be six collaboration programmes in total, with the companies working together using Avila's Avilomics platform to design products which aim to target one of six signalling proteins that are critical in tumour cells.

These proteins are difficult to target with conventional pharmaceutical treatments, but are thought to have the potential to respond to covalent drugs.

Covalent treatments have the ability to establish a stronger molecular bond than conventional therapies, allowing them to shut down the activity of proteins responsible for certain diseases. This technique is called 'protein silencing'.

"Avila Therapeutics' expertise in designing targeted covalent drugs offers a new way to solve difficult pharmacological challenges in oncology and to address important cancer targets," said Dr Debasish Roychowdhury, senior vice president and head of oncology, S-A. "We believe that Avila's approach adds to our growing portfolio of research capabilities that will provide medicines which substantially improve patient outcomes."

20th December 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics